BACKGROUND: Recent studies have reported a high comorbidity between posttraumatic stress disorder (PTSD) and psychotic symptoms, and it has been hypothesized that PTSD with comorbid psychosis is a severe form of PTSD. Few studies have examined the neurobiology of PTSD with comorbid psychosis. If PTSD with secondary psychotic symptoms (PTSD-SP) is a severe form of PTSD, then it might be expected to show more extreme perturbations in the neuroendocrine patterns that characterize PTSD. METHODS: Patients with PTSD with secondary psychotic symptoms (PTSD-SP), PTSD without psychosis, and healthy comparison subjects were compared for differences in cerebrospinal fluid concentrations of corticotropin-releasing factor (CRF) and somatotropin-release-inhibiting hormone (SRIF). RESULTS: The PTSD-SP subjects had significantly higher mean levels of CRF than either the PTSD or control subjects (p <.01). The three groups showed similar SRIF levels. CONCLUSIONS: These data implicate abnormalities in the secretion of CRF with the production of secondary psychotic symptoms in PTSD. This finding supports the validity of PTSD-SP as a PTSD subtype and as a severe form of PTSD.
BACKGROUND: Recent studies have reported a high comorbidity between posttraumatic stress disorder (PTSD) and psychotic symptoms, and it has been hypothesized that PTSD with comorbid psychosis is a severe form of PTSD. Few studies have examined the neurobiology of PTSD with comorbid psychosis. If PTSD with secondary psychotic symptoms (PTSD-SP) is a severe form of PTSD, then it might be expected to show more extreme perturbations in the neuroendocrine patterns that characterize PTSD. METHODS:Patients with PTSD with secondary psychotic symptoms (PTSD-SP), PTSD without psychosis, and healthy comparison subjects were compared for differences in cerebrospinal fluid concentrations of corticotropin-releasing factor (CRF) and somatotropin-release-inhibiting hormone (SRIF). RESULTS: The PTSD-SP subjects had significantly higher mean levels of CRF than either the PTSD or control subjects (p <.01). The three groups showed similar SRIF levels. CONCLUSIONS: These data implicate abnormalities in the secretion of CRF with the production of secondary psychotic symptoms in PTSD. This finding supports the validity of PTSD-SP as a PTSD subtype and as a severe form of PTSD.
Authors: Richard L Hauger; J Alberto Olivares-Reyes; Frank M Dautzenberg; James B Lohr; Sandra Braun; Robert H Oakley Journal: Neuropharmacology Date: 2011-11-25 Impact factor: 5.250
Authors: E Keen-Rhinehart; V Michopoulos; D J Toufexis; E I Martin; H Nair; K J Ressler; M Davis; M J Owens; C B Nemeroff; M E Wilson Journal: Mol Psychiatry Date: 2008-08-12 Impact factor: 15.992
Authors: Sabra S Inslicht; Anne Richards; Erin Madden; Madhu N Rao; Aoife O'Donovan; Lisa S Talbot; Evelyn Rucker; Thomas J Metzler; Richard L Hauger; Thomas C Neylan Journal: Psychopharmacology (Berl) Date: 2014-06-21 Impact factor: 4.530
Authors: Jessica Deslauriers; Mate Toth; Miriam Scadeng; Benjamin S McKenna; Robert Bussell; Jodi Gresack; Robert Rissman; Victoria B Risbrough; Gregory G Brown Journal: Psychiatry Res Neuroimaging Date: 2020-07-15 Impact factor: 2.376
Authors: Julie E Finnell; Brandon L Muniz; Akhila R Padi; Calliandra M Lombard; Casey M Moffitt; Christopher S Wood; L Britt Wilson; Lawrence P Reagan; Marlene A Wilson; Susan K Wood Journal: Biol Psychiatry Date: 2018-01-31 Impact factor: 13.382
Authors: J Douglas Bremner; Matthew T Wittbrodt; Amit J Shah; Bradley D Pearce; Nil Z Gurel; Omer T Inan; Paolo Raggi; Tené T Lewis; Arshed A Quyyumi; Viola Vaccarino Journal: J Nerv Ment Dis Date: 2020-03 Impact factor: 2.254